🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Steroid Sparing Regimen With Olanzapine and Palonosetron for Emetic Prevention for High Dose Cisplatin

RecruitingPhase 2Ages 18 Years - anyAllMahidol University
NCT07699276 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

A phase II study evaluating dexamethasone sparing regimen with olanzapine and palonosetron for patients receiving high dose cisplatin to prevent chemotherapy induced nausea and vomiting

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * histologically confirmed solid malignancy * scheduled for first cycle of cisplatin at dosage of at least 50 mg/m2 Exclusion Criteria: * pregnancy * pelvic or abdominal radiation within 4 weeks * uncontrolled brain metastasis * other moderate or high emetic risk chemotherapy on day 2-5 * untreated gut obstruction * known allergy or severe adverse effect from palonosetron or olanzapine * AST/ ALT \> 2.5x or serum creatinine clearance less than 50 ml/min
💊

What it tests

  • dexamethasone sparing
📍

Where

1 site
Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Thailand
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy